Patent ID: 8753673
Filing Date: 2014-06-17
Classification: A61K

Abstract:
1. A method of delivering high pay-load of a therapeutic agent for an eye disease to neovascularization sites of the eyes of a patient, comprising: systemically administering a liposome composition to said patient by intravenous injection; wherein the liposome composition has a mean particle diameter of about 30 to 200 nm comprising a particle-forming component composed of vesicle-forming lipids selected from the group consisting of amphipathic lipids having hydrophobic and polar head group moieties alone or in combination, and an agent-carrying component that contains one or more negatively or positively charged groups, wherein said agent-carrying component forms a stable, soluble salt with the therapeutic agent via electrostatic charge-charge interaction so as to prevent or minimize the release of the therapeutic agent to blood circulation and allow the therapeutic agent to be delivered to and accumulate at the neovascularization sites at the back of the eyes 24 hours after the systemic administration of the liposome composition to the patient, and wherein the liposome lacks a targeting moiety for a cell surface marker.